المؤلفون: Rafael Rosell, Alice T. Shaw, Ali Zeaiter, Shirish M. Gadgeel, Emmanuel Mitry, Bogdana Balas, Jin S. Ahn, Maurice Perol, Johannes Noe, Sai-Hong Ignatius Ou, Peter N. Morcos, D. Ross Camidge, Solange Peters, Tony Mok, Dong Wan Kim, Rafal Dziadziuszko, Sophie Golding

المساهمون: ALEX Trial Investigators, Nordman, I., Pittman, K., Dear, R., Lwin, Z., Briggs, P., Pavlakis, N., Ceric, T., Mehic, B., Stanetic, M., Franke, F.A., Castro, G., Santo Borges, G., Pereira, J., Brust, L., Santos, L., Cruz, M., Ribeiro, R., De Azevedo, S., Neron, Y.V., Sangha, R., Cohen, V., Burkes, R., Abdelsalam, M., Yadav, S., Cheema, P., Yanez, E., Aren, O., Zhou, C., Zhang, L., Liu, X., Corrales Rodriguez, L., Meldgaard, P., Soerensen, J.B., McCulloch, T., Rodriguez, N., Gaafar, R., Abdel Azeem, H., Coudert, B., Moro-Sibilot, D., Lena, H., Bennouna, J., Cortot, A., Veillon, R., Cadranel, J., Barlesi, F., Reck, M., Mezger, J., von Pawel, J., Fischer, J.R., Dickgreber, N.K., Zarogoulidis, K., Syrigos, K., Georgoulias, V., Agelaki, S., Castro-Salguero, H., Ho, J., Chan, S.H., Cheng, C.K., Ng, A., Stemmer, S., Wollner, M., Gottfried, M., Dudnik, J., Cyjon, A., Heching, N., Novello, S., Tiseo, M., Platania, M., Misino, A., Gridelli, C., Ciardiello, F., Favaretto, A., De Marinis, F., Longo, F., Bordonaro, R., Dazzi, C., Chiari, R., Mercuri, E., Macedo, E., Rodriguez Cid, J.R., McKeage, M., Vera, L., Morón Escobar, H.D., Rodriguez, M., Mas, L., Ramlau, R., Kowalski, D., Szczesna, A., Kazarnowicz, A., Milanowski, J., Luboch-Kowal, J., Oliveira, J., Barata, F., Almodovar, T., Lee, J.S., Cho, B.C., Kim, S.W., Han, J.Y., Karaseva, N., Stroyakovskii, D., Kuzmin, A., Smolin, A., Laktionov, K., Ragulin, Y., Filippov, A., Levchenko, E., Jovanovic, D., Perin, B., Andric, Z., Soo, R., Tan, E.H., De Castro Carpeno, J., Provencio Pulla, M., Garrido Lopez, P., Felip Font, E., Morano Bueno, T., Sanchez, A., Isla Casado, D., Ponce Aix, S., Reguart Aransay, N., Viteri Ramirez, S., Rodriguez Abreu, D., Sanchez Torres, J.M., Massuti Sureda, B., Ramos Vazquez, M., Tabernero, J.M., Curioni, A., Rothschild, S., Scherz, A., Chiu, C.H., Su, W.C., Yang, CHJ, Chang, G.C., Hsia, T.C., Yang, C.T., Tharavichitkul, E., Pongthai, P., Arpornwirat, W., Geater, S., Srimuninnimit, V., Sriuranpong, V., Demirkazik, A., Goker, E., Harputluoglu, H., Cicin, I., Kose, F., Erman, M., Bondarenko, I., Vinnyk, Y., Shparyk, Y., Golovko, Y., Lal, R., Forster, M., Califano, R., Skailes, G., Thompson, J., Mekhail, T., Polikoff, J., Spigel, D., Waqar, S., Hermann, R., Deo, E., Simon, G., Rybkin, I., Kaywin, P.R., Uyeki, J., Gubens, M., Limaye, S., Gerber, D.E., Leal, T., Spira, A.I., Bazhenova, L., Cetnar, J., Socinski, M., Jahanzeb, M., Kabbinavar, F., Lawler, W.E., Hancock, M.R., Raez, L.E., DiCarlo, B.A., Lowe, T.E., Fidler, M., Ross, H., Davidson, S.J., Sanchez, J.D., Hamm, J., Kerr, S., Belman, N., Baker, S., Naraev, B., Jung, G., Edelman, M., Feldman, L., Belani, C., Pakkala, S.

المصدر: Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
The New England journal of medicine, vol. 377, no. 9, pp. 829-838

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Alectinib, medicine.medical_specialty, Pathology, Lung Neoplasms, Brigatinib, Pyridines, medicine.drug_class, Carbazoles, Antineoplastic Agents, Kaplan-Meier Estimate, Aged, 80 and over, Animals, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Carbazoles/adverse effects, Carbazoles/therapeutic use, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/mortality, Central Nervous System Neoplasms/drug therapy, Central Nervous System Neoplasms/secondary, Disease-Free Survival, Female, Follow-Up Studies, Humans, Intention to Treat Analysis, Lung Neoplasms/drug therapy, Lung Neoplasms/mortality, Middle Aged, Piperidines/adverse effects, Piperidines/therapeutic use, Protein Kinase Inhibitors/adverse effects, Protein Kinase Inhibitors/therapeutic use, Pyrazoles/adverse effects, Pyrazoles/therapeutic use, Pyridines/adverse effects, Pyridines/therapeutic use, Receptor Protein-Tyrosine Kinases/analysis, Receptor Protein-Tyrosine Kinases/antagonists & inhibitors, Young Adult, Central Nervous System Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Piperidines, Carcinoma, Non-Small-Cell Lung, hemic and lymphatic diseases, Internal medicine, medicine, Anaplastic lymphoma kinase, Lung cancer, Protein Kinase Inhibitors, Crizotinib, Ceritinib, business.industry, Receptor Protein-Tyrosine Kinases, General Medicine, medicine.disease, Lorlatinib, ALK inhibitor, 030104 developmental biology, 030220 oncology & carcinogenesis, Pyrazoles, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18d35d488c552e94e96cbf18b7922921Test
https://doi.org/10.1056/nejmoa1704795Test

المؤلفون: Stellar Levy, Braden Miller, Curtis J. Perry, Susan M. Kaech, Alexandra Kuhlmann, Tianxia Guan, Fernando J. de Miguel, Daniel Zelterman, Camila Robles-Oteiza, Deborah Ayeni, William W. Lockwood, Ping-Chih Ho, Robert J. Homer, Katerina Politi, Mmaserame Gaefele, Gerald Krystal, Zongzhi Liu

المصدر: Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 172
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Lung Neoplasms, T-Lymphocytes, EGFR, Immunology, Antineoplastic Agents, Mice, Transgenic, Mouse models, lcsh:RC254-282, 03 medical and health sciences, Erlotinib Hydrochloride, 0302 clinical medicine, Immune system, Targeted therapies, medicine, Tumor Microenvironment, Immunology and Allergy, Animals, Epidermal growth factor receptor, Lung cancer, Protein Kinase Inhibitors, Pharmacology, Tumor microenvironment, CD40, Oncogene, biology, business.industry, Antineoplastic Agents/therapeutic use, ErbB Receptors/genetics, ErbB Receptors/immunology, Erlotinib Hydrochloride/therapeutic use, Lung Neoplasms/drug therapy, Lung Neoplasms/genetics, Lung Neoplasms/immunology, Mutation, Oncogenes, Protein Kinase Inhibitors/therapeutic use, T-Lymphocytes/drug effects, T-Lymphocytes/immunology, Tumor Microenvironment/drug effects, Tumor Microenvironment/immunology, Immunotherapies, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, respiratory tract diseases, ErbB Receptors, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, biology.protein, Cancer research, Molecular Medicine, Erlotinib, business, Tyrosine kinase, medicine.drug, Research Article

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f2f07589f052ce53139b4376d5454b5Test
https://pubmed.ncbi.nlm.nih.gov/31291990Test

المؤلفون: David Tulasne, Alexis B. Cortot, Marie Wislez, Zoulika Kherrouche, C. Descarpentries, Alessandro Furlan, Simon Baldacci

المساهمون: Mécanismes de la Tumorigénèse et Thérapies Ciblées - UMR 8161 (M3T), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), This work was supported by the CNRS, the Institut Pasteur de Lille, and INSERM, and by grants from the 'Ligue contre le Cancer, comité Nord,' the 'Association pour la Recherche sur le Cancer,' the 'Institut National du Cancer,' the 'Cancéropôle Nord-Ouest,' and the 'Site de Recherche Intégrée sur le Cancer, SIRIC ONCOLille.', FURLAN, Alessandro, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

المصدر: JNCI: Journal of the National Cancer Institute
JNCI: Journal of the National Cancer Institute, 2017, 109 (5), pp.djw262. ⟨10.1093/jnci/djw262⟩
JNCI: Journal of the National Cancer Institute, Oxford University Press (OUP), 2017, 109 (5), pp.djw262. ⟨10.1093/jnci/djw262⟩

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, neoplasms, medicine.disease_cause, protein-tyrosine kinase inhibitor, exons, Receptor tyrosine kinase, Exon, 0302 clinical medicine, MESH: Molecular Targeted Therapy, Medicine, MESH: Animals, Epidermal growth factor receptor, Molecular Targeted Therapy, Receptor, Mutation, biology, MESH: Gene Expression Regulation, Neoplastic, Protein-Tyrosine Kinases, Proto-Oncogene Proteins c-met, 3. Good health, Gene Expression Regulation, Neoplastic, MESH: Neoplasms/drug therapy, Oncology, 030220 oncology & carcinogenesis, Tyrosine kinase, MESH: Mutation, MESH: Biomarkers, Tumor/genetics, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Protein-Tyrosine Kinases/antagonists & inhibitors, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH: Neoplasms/genetics, Biomarkers, Tumor, Animals, Humans, cancer, Protein Kinase Inhibitors, MESH: Humans, business.industry, Cancer, MESH: Exons, medicine.disease, MESH: Protein Kinase Inhibitors/therapeutic use, MESH: Proto-Oncogene Proteins c-met/genetics, MESH: Neoplasms/diagnosis, 030104 developmental biology, Protein kinase domain, biology.protein, Cancer research, mutation, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::783dd5662b5335ef9e7f18d69d56fff9Test
https://hal.science/hal-02413937Test